XTL Biopharmaceuticals
XTLB
3 hedge funds and large institutions have $515K invested in XTL Biopharmaceuticals in 2020 Q1 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 1 closing their positions.
0.03% more ownership
Funds ownership: 8.05% → 8.08% (+0.03%)
14% less capital invested
Capital invested by funds: $596K → $515K (-$81K)
25% less funds holding
Funds holding: 4 → 3 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$3.99K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$2K |
XTLB Hedge Fund Activity: Q1 2020 in Review
3 of the 4,548 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q1 2020, worth a combined $515K — down 14% from $596K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of XTLB and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 1 added.
The largest buyer was Morgan Stanley, adding an estimated $3.99K. The largest seller was UBS Group, exiting entirely with an estimated $2K sold.
- 3 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q1 2020, down from 4 in Q4 2019.
- Funds reported $515K of XTL Biopharmaceuticals stock for Q1 2020, down 14% quarter-over-quarter.
- 0 funds opened new XTL Biopharmaceuticals positions in Q1 2020 and 1 closed out, a net change of -1 holder.
- The largest XTL Biopharmaceuticals buyer in Q1 2020 was Morgan Stanley, an estimated $3.99K added.
- The largest XTL Biopharmaceuticals seller in Q1 2020 was UBS Group, an estimated $2K sold.
Based on aggregated 13F filings for Q1 2020.